BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ION337 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ION337\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07531745-9008@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:ION337: Phase 1/2 readout est. (NCT07531745)
DESCRIPTION:ION337\, phase 1/2\, Epilepsy.\nStudy: ASCEND: Safety and Toler
 ability of ION337 for the Treatment of Dravet Syndrome\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ion337#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07531745
URL:https://assetmemo.bio/drug/ion337#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
